Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)

Market Cap	44.89B
Revenue (ttm)	6.80B
Net Income (ttm)	958.67M
Shares Out	855.14M
EPS (ttm)	1.11
PE Ratio	50.39
Forward PE	40.40
Dividend	0.57 (1.00%)
Ex-Dividend Date	Jul 12, 2024

Volume	12,933,373
Average Volume	13,400,854
Open	57.80
Previous Close	55.84
Day's Range	55.31 - 58.45
52-Week Range	46.41 - 82.79
Beta	0.94
RSI	55.80
Earnings Date	Mar 28, 2025

About SHE:300347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 9,701
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300347

Financial Performance

In 2023, SHE:300347's revenue was 7.38 billion, an increase of 4.21% compared to the previous year's 7.09 billion. Earnings were 2.02 billion, an increase of 0.91%.